AstraZeneca (LON:AZN) received a GBX 9,000 ($117.59) target price from research analysts at Credit Suisse Group in a research note issued on Monday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 17.97% from the company’s current price.
Several other research firms have also weighed in on AZN. Jefferies Financial Group set a GBX 8,850 ($115.63) target price on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, April 30th. UBS Group set a GBX 8,000 ($104.52) price objective on AstraZeneca and gave the company a “buy” rating in a report on Friday, April 30th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reissued a “buy” rating and set a £100 ($130.65) target price on shares of AstraZeneca in a research note on Thursday, April 8th. Berenberg Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Friday, April 16th. Finally, Barclays set a £100 ($130.65) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Monday, March 22nd. Four investment analysts have rated the stock with a sell rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of GBX 8,886.25 ($116.10).
Shares of AZN stock opened at GBX 7,629 ($99.67) on Monday. The company has a current ratio of 0.87, a quick ratio of 0.67 and a debt-to-equity ratio of 155.65. AstraZeneca has a twelve month low of GBX 6,736 ($88.01) and a twelve month high of £101.20 ($132.22). The company’s 50-day moving average price is GBX 7,333 and its 200-day moving average price is GBX 7,569.54. The stock has a market cap of £100.15 billion and a price-to-earnings ratio of 34.76.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Read More: Quiet Period
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.